Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
about
Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineDevelopment and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary DiseaseDiet-Induced Obesity Does Not Alter Tigecycline Treatment Efficacy in Murine Lyme Disease.Pharmacokinetic and pharmacodynamic evaluation of tigecycline.Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.Determination of tigecycline in human plasma by LC-MS/MS and its application to population pharmacokinetics study in Chinese patients with hospital-acquired pneumonia.Population pharmacokinetics of high-dose tigecycline in patients with sepsis or septic shock.
P2860
Q35026616-4CDC553F-7AED-4FDA-8F73-22008C341DE6Q35666608-9CA8AD7C-976B-4C53-9C19-AF5D82064BFEQ35689185-8450E58A-647E-4352-8E28-166FCB08E8A9Q36035161-CD855003-1378-41C1-9816-1ED6D36069F6Q36757628-4A6E464F-3591-4D69-9D5D-D6DF952D8433Q36887811-A6453F37-A1F1-4BAE-888E-EDA8418128E1Q37662663-C25538DE-A24A-45EE-979A-1FF17E4582F5Q37940546-F261013C-2A76-4A7C-9DAE-10045D9423E3Q40140013-6E8A692C-22A2-4F0A-BB43-A2E6F18BBC12Q40175198-4F87A2F8-8C74-4568-AE1C-A3D4DDDE90F8Q41111507-6E3208E7-CB04-41B2-891F-5BE2175FE2FCQ41833657-E2D85E27-346A-4688-9794-2C59EB19F64AQ47662018-E3947063-D48D-4DF9-B871-E3B77529E09AQ47983248-B09E9033-78E9-403C-A670-4EFB1DD54D83Q49874670-12E8D56A-38D0-430F-A97C-087660320D7F
P2860
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@ast
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@en
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@nl
type
label
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@ast
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@en
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@nl
prefLabel
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@ast
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@en
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@nl
P2093
P2860
P356
P1476
Tigecycline population pharmac ...... r hospital-acquired pneumonia.
@en
P2093
Alan Forrest
Angel Cooper
Christopher M Rubino
Gary Dukart
Joan Korth-Bradley
Paul G Ambrose
Sujata M Bhavnani
P2860
P304
P356
10.1128/AAC.01414-09
P407
P577
2010-10-04T00:00:00Z